These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19199878)

  • 1. The perils of Alzheimer's drug development.
    Schneider LS; Lahiri DK
    Curr Alzheimer Res; 2009 Feb; 6(1):77-8. PubMed ID: 19199878
    [No Abstract]   [Full Text] [Related]  

  • 2. Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.
    Becker RE; Unni LK; Greig NH
    Curr Alzheimer Res; 2009 Feb; 6(1):79-81. PubMed ID: 19199879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why so few drugs for Alzheimer's disease? Are methods failing drugs?
    Becker RE; Greig NH
    Curr Alzheimer Res; 2010 Nov; 7(7):642-51. PubMed ID: 20704560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving drug trials for mild to moderate Alzheimer's disease.
    Hogan DB
    Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S97-102. PubMed ID: 17469691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physostigmine in Alzheimer's disease.
    Smith CM; Swash M
    Lancet; 1979 Jan; 1(8106):42. PubMed ID: 83485
    [No Abstract]   [Full Text] [Related]  

  • 6. On weighted composite scores for early Alzheimer's trials.
    Jin K; Cameron B; Dunn B
    Pharm Stat; 2019 Mar; 18(2):239-247. PubMed ID: 30565432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Primary prevention of dementia in Alzheimer's disease: a perspective from prevention research in cardiovascular disease and stroke.
    Fillit H; Nash DT; Shineman D
    Alzheimers Dement; 2009 Mar; 5(2):149-53. PubMed ID: 19328448
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer's disease.
    Cain JW
    Am J Psychiatry; 1986 Jul; 143(7):910-2. PubMed ID: 3717434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease?
    Gauthier S; Poirier J
    Alzheimers Dement; 2009 Mar; 5(2):147-8. PubMed ID: 19328447
    [No Abstract]   [Full Text] [Related]  

  • 10. A consideration of the guidelines for investigating potential new drugs in humans in the United Kingdom.
    McGillion FB
    Methods Find Exp Clin Pharmacol; 1979 Apr; 1(1):45-50. PubMed ID: 552581
    [No Abstract]   [Full Text] [Related]  

  • 11. Physostigmine effects in Alzheimer's disease: relationship to dementia severity.
    Schwartz AS; Kohlstaedt EV
    Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral physostigmine in Alzheimer's disease.
    Davis KL; Mohs RC; Davis BM; Horvath TB; Greenwald BS; Rosen WG; Levy MI; Johns CA
    Psychopharmacol Bull; 1983; 19(3):451-3. PubMed ID: 6635123
    [No Abstract]   [Full Text] [Related]  

  • 13. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Facilitating Alzheimer's disease drug development in the United States.
    Aisen PS
    Alzheimers Dement; 2009 Mar; 5(2):125-7. PubMed ID: 19328440
    [No Abstract]   [Full Text] [Related]  

  • 14. A new colonialism?--Conducting clinical trials in India.
    Nundy S; Gulhati CM
    N Engl J Med; 2005 Apr; 352(16):1633-6. PubMed ID: 15843665
    [No Abstract]   [Full Text] [Related]  

  • 15. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl.
    Sunderland T; Molchan S; Lawlor B; Martinez R; Mellow A; Martinson H; Putnam K; Lalonde F
    Int Psychogeriatr; 1992; 4 Suppl 2():291-309. PubMed ID: 1288668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open access chemical and clinical probes to support drug discovery.
    Edwards AM; Bountra C; Kerr DJ; Willson TM
    Nat Chem Biol; 2009 Jul; 5(7):436-40. PubMed ID: 19536100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral physostigmine treatment of patients with Alzheimer's disease.
    Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL
    Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term administration of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies.
    Mohs RC; Davis BM; Greenwald BS; Mathé AA; Johns CA; Horvath TB; Davis KL
    J Am Geriatr Soc; 1985 Nov; 33(11):749-57. PubMed ID: 2865282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease.
    Jotkowitz S
    Ann Neurol; 1983 Dec; 14(6):690-1. PubMed ID: 6360031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.